Literature DB >> 2049579

Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon.

K Darton1, C M Black.   

Abstract

Thermographic images of the hands of patients with primary and secondary Raynaud's phenomenon and of a group of normal subjects, recorded before and after cold provocation using a pyroelectric vidicon thermal imaging system, showed differences in thermal distribution patterns that were characteristic of primary Raynaud's phenomenon (RP), scleroderma (RS) and normal, and were exaggerated by cold provocation. The responses to cold challenge, assessed by computing the mean temperature of the hand as it recovered from cold challenge and plotting these values against time to produce a rewarming curve, were also characteristic of the patient and the normal groups, and gave an indication of the severity of circulatory impairment. Methods are described for the simple numerical characterization of these parameters.

Entities:  

Mesh:

Year:  1991        PMID: 2049579     DOI: 10.1093/rheumatology/30.3.190

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  4 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

2.  Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma.

Authors:  A Luksch; G Rainer; D Koyuncu; P Ehrlich; T Maca; M E Gschwandtner; C Vass; L Schmetterer
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

Review 3.  Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; S Clark
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

Review 4.  Evidence-based management of Raynaud's phenomenon.

Authors:  Ariane L Herrick
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-11-20       Impact factor: 5.346

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.